MMP-9-IN-14 是一种 MMP-9 抑制剂(IC50 = 34.46 μM),可诱导癌细胞发生 G1 期细胞周期阻滞和 caspase 依赖性细胞凋亡(apoptosis),促进磷酸化 γH2AX 的积累,抑制癌细胞的迁移和侵袭,下调癌细胞中 MMP-2、MMP-9 和 hTERT 的表达,并在动物模型中抑制肿瘤生长及血管趋向性扩散,因此可用于肺腺癌、宫颈癌、结直肠癌等癌症的研究。
MMP-9-IN-14
产品编号: MS-H34644 分子式: C25H18Cl2N2O2S 分子量: 481.39
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

MMP-9-IN-14 是一种 MMP-9 抑制剂(IC50 = 34.46 μM),可诱导癌细胞发生 G1 期细胞周期阻滞和 caspase 依赖性细胞凋亡(apoptosis),促进磷酸化 γH2AX 的积累,抑制癌细胞的迁移和侵袭,下调癌细胞中 MMP-2、MMP-9 和 hTERT 的表达,并在动物模型中抑制肿瘤生长及血管趋向性扩散,因此可用于肺腺癌、宫颈癌、结直肠癌等癌症的研究。

生物实验数据

生物活性 MMP-9-IN-14 is an MMP-9 inhibitor (IC50 = 34.46 μM) that induces G1 cell cycle arrest and caspase-dependent apoptosis in cancer cells, promotes the accumulation of phosphorylated γH2AX, inhibits cancer cell migration and invasion, downregulates the expression of MMP-2, MMP-9, and hTERT in cancer cells, and suppresses tumor growth and vasculogenic dissemination in animal models, making it useful for research on cancers such as lung adenocarcinoma, cervical cancer, and colorectal cancer.
IC50 & Target

MMP-9

34.46 μM (IC50)

Caspase 3

 

Caspase-7

 

MMP-2

 

体外研究
(In Vitro)


MMP-9-IN-14 (Compound 24) (0.39-100 μM; 30 min, 37°C) 可直接抑制重组人 MMP-9 酶活性,其 IC50 为 34.46 μM。
MMP-9-IN-14 (0-50 μM;72 h) 抑制多种细胞系 (A-549,H-226,H-460,HCT-116,Hep G2,HeLa,HaCaT, MRC-5) 的活力,IC50 值分别为 2.23,2.34,,5.49,4.95,51.41,2.75,8.89,18.47 μM。
MMP-9-IN-14 (2.23 μM; 24-72 h) 可在 A-549 细胞中诱导 G1 期细胞周期阻滞。
MMP-9-IN-14 (2.23 μM; 24-72 h) 可诱导 A-549 细胞发生 caspase 依赖性细胞凋亡。
MMP-9-IN-14 (2.23 μM; 24-72 h) 在 A-549 细胞中增加 γH2AX 阳性细胞数量,累积 DNA 损伤。
Compound 24 (5-30 μM; 0-24 h) 抑制 A-549 癌细胞的迁移和侵袭。
Compound 24 (15-30 μM; 48 h) 下调 A-549 细胞中转移相关基因 (MMP-2, MMP-9) 和 hTERT 的表达,并能强效抑制 TGF-β1 诱导的 MMP 表达。
Compound 24 (10-50 μM; 72 h) 抑制 A-549 3D 球状体的增殖,在具有生理相关性的 3D 模型中展现出抗转移活性。

Cell Cycle Analysis

Cell Line: A-549 cells
Concentration: 2.23 μM
Incubation Time: 24 h, 48 h, 72 h
Result: Caused a significant decrease in the S-phase population after 24 h treatment. Induced cell accumulation in the G1 phase with a reduction in G2/M content by 48 h treatment.
Induced a marked G1-phase arrest, with ~65% of cells in G1 phase and concurrent reductions in S and G2/M fractions at 72 h treatment.

Cell Viability Assay

Cell Line: A-549,H-226,H-460,HCT-116,Hep G2,HeLa,HaCaT, MRC-5 cells
Concentration: 0-50 μM
Incubation Time: 72 h
Result: Inhibited the viability of various cell lines (A-549, H-226, H-460, HCT-116, Hep G2, HeLa, HaCaT, MRC-5), with IC50 values of 2.23, 2.34, 5.49, 4.95, 51.41, 2.75, 8.89, and 18.47, respectively.

Apoptosis Analysis

Cell Line: A-549 cells
Concentration: 2.23 μM
Incubation Time: 24 h, 48 h, 72 h
Result: Caused a increase in apoptosis, with ~10% early apoptotic and ~8% late apoptotic cells after 24 h treatment.
Increased early apoptosis to ~11% and late apoptosis to ~15%, with ~70% cell viability remaining at 48 h treatment.
Increased caspase-3/7 activity by ~5-fold at 24 h, ~5-6-fold at 48 h, and ~7-fold at 72 h compared to controls.

Cell Migration Assay

Cell Line: A-549 cells
Concentration: 5, 10, 15 μM
Incubation Time: 0 h, 6 h, 12 h,
18 h, 24 h
Result: Significantly and in a concentration-dependent manner inhibited cell migration and delayed wound closure.

Cell Invasion Assay

Cell Line: A-549 cells
Concentration: 15, 30 μM
Incubation Time: 24 h
Result: Reduced the number of invading A-549 cells to ~65% of control levels at 15 μM. Reduced the number of invading cells to ~25% of control levelsat 30 μM.

Real Time qPCR

Cell Line: A-549 cells (with or without TGF-β1 stimulation)
Concentration: 15, 30 μM
Incubation Time: 48 h
Result: Significantly suppressed TGF-β1-induced MMP-2 and MMP-9 mRNA expression: at 15 μM, MMP-2 expression was reduced by ~60% and MMP-9 by ~70%; at 30 μM, both MMP-2 and MMP-9 mRNA levels were reduced to near baseline.
Downregulated hTERT expression: at 15 μM, hTERT expression was reduced by ~50%, and at 30 μM, was almost undetectable.
体内研究
(In Vivo)

MMP-9-IN-14 (compound 24) (25-50 μM; 局部给药;单次给药) 可抑制鸡胚尿囊膜 (CAM) 上 A-549 肿瘤生长,并可完全抑制肿瘤细胞的血管趋向性播散,且未检测到胚胎毒性。

Animal Model: A-549 Xenotransplantation chorioallantoic membrane (CAM) model
Dosage: 25 μM; 50 μM
Administration: topical; single administration
Result: Reduced median tumour area. Showed weaker, less homogeneous CellTracker Green signals in treated tumours, indicating reduced tumour cell viability/density.
Revealed a near-complete absence of disseminated fluorescent tumour cells in distal CAM regions, compared to frequent vasculotropic spread in vehicle controls.

化学信息

分子量 481.39
分子式 C25H18Cl2N2O2S

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础